Companies › Albireo, an Ipsen Company
1 active drug program in 2 registered trials: 2 Phase 3; Gastroenterology, Other; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Odevixibat Ileal bile acid transporter inhibitor | SLC10A2 | Phase 3 | Biliary Atresia; Alagille Syndrome | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05426733 | Odevixibat | Phase 3 | Biliary Atresia | Gastroenterology | Oct 2026 |
| NCT05035030 | Odevixibat | Phase 3 | Alagille Syndrome | Other | Feb 2027 |
Dr. F. Köhler Chemie GRIN Therapeutics Mirum Pharmaceuticals Getz Pharma Huons Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.